| Cases |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Business > Business > Differences Between Mergers and Acquisitions |
|
Cases - Differences Between Mergers and Acquisitions
Although the terms merger and acquisition are often used as though they are synonymous, they mean According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product different things. The differences between a merger and acquisition are important to value, negotia ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in te, and structure a client's transaction. Mergers and acquisitions both involve one or multiple co lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. mpanies purchasing all or part of another company. The main distinction between a merger and an ac here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe quisition is how they are financed. A merger happens when two firms, often of about the same size d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro , agree to move forward and exist as a single new company rather than remain separately owned and ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc operated. This kind of action is more specifically referred to as a "merger of equals." Mergers ar easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi e often financed by a stock swap, in which the stock owners in both companies receive an equivalen nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically t quantity of stock in the new company. The stocks of both companies are surrendered and new compa and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ ny stock is issued in its place. On the other hand, when one company takes over another company an ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi d clearly establishes itself as the new owner, the purchase is called an acquisition. Legally, the ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a target company ceases to exist, the buyer swallows the business and the buyer's stock continues t dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod o be traded. Acquisition refers to two unequal companies becoming one and the financing can involv cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin e a cash and debt combination, all cash, stocks, or other equity of the company. A purchase deal tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen will be called a merger when the CEOs of both the companies agree that joining together is in the t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel best interest of both of their companies. When the deal is unfriendly - that is, when the target c ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust ompany does not want to be purchased, it is regarded as an acquisition. Whether a purchase is con y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products sidered a merger or an acquisition, in reality depends on whether the purchase is friendly or host . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de ile and how it is announced. In other words, the actual difference lies in how the purchase is com elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip municated to and received by the target company's board of directors, shareholders, and employees. tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:Is It Resistance Or Is It Fear - What's The Difference? Business Debt Settlement - Choosing the Right Service Provider for Business Debt Settlement
|